Mindblown: a blog about philosophy.
-
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT® Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023.
-
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
5,000 patients with non-small cell lung cancer enrolled to be monitored up to three years BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests…
-
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data…
-
Your Blog Post Title Here…
-
https://investors.biodesix.com/news-releases/news-release-details/biodesix-participate-william-blairs-43rd-annual-growth-stock
-
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
May 31, 2023 at 6:00 AM EDT Download PDF BOULDER, Colo.–(BUSINESS WIRE)–May 31, 2023– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1×1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held…
-
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
-
Robin Harper Cowie Appointed to Colorado BioScience Association’s Board of Directors
May 24, 2023 at 6:00 AM MT
-
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
May 18, 2023 at 7:00 AM EDT
-
Biodesix Announces First Quarter 2023 Results and Highlights
May 11, 2023 at 4:01 PM EDT
Got any book recommendations?